Glutathione-responsive Prodrugs
Glutathione-responsive Prodrugs - Related Videos
08:10
Measuring Glutathione-induced Feeding Response in Hydra
0 Views •
Cited by 9 •
2014
Here we describe a simple assay for the quantification of the feeding response in hydra induced by the reduced form of glutathione. This assay relies on measuring the distance between the apical end of the tentacle and mouth of hydra.
01:30
Prodrugs
0 Views •
2023
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration. Prodrugs help overcome...
08:54
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
0 Views •
2023
This protocol describes the fabrication and characterization of a photoresponsive prodrug-dye nanoassembly. The methodology for drug release from the nanoparticles by light-triggered disassembly, including the light irradiation setup, is explicitly described. The drugs released from the nanoparticles following light irradiation exhibited excellent anti-proliferation effects on human colorectal tumor cells.
01:22
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
0 Views •
2025
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion. Several distinctive characteristics distinguish glutathione conjugation from other phase II...
14:57
Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
0 Views •
Cited by 14 •
2020
Glutathione S-transferases (GSTs) are detoxification enzymes involved in the metabolism of numerous chemotherapeutic drugs. Overexpression of GSTs is correlated with cancer chemotherapy resistance. One way to counter this phenotype is to use inhibitors. This protocol describes a method using a spectrophotometric assay to screen for potential GST inhibitors.
FAQs
Release begins when glutathione’s thiol group reacts with a glutathione-sensitive linker, commonly a disulfide bond. Thiol-disulfide exchange or reduction disrupts that linkage, separating the carrier or masking group from the therapeutic molecule. The structural change converts the derivative toward its active form, making the intracellular reducing environment the key trigger for payload liberation.
The strategy uses a difference between glutathione located inside cells and conditions encountered elsewhere. A linker that responds to cellular glutathione can undergo cleavage after the prodrug reaches intracellular reducing conditions. This spatially associated trigger may support more selective release at the cellular site, connecting the drug’s activation pattern with the intended treatment context.
The linker determines how the prodrug responds to glutathione, while the carrier or masking group controls how the active drug is presented before release. Together, these structural elements can influence whether the payload stays less active, how it is separated intracellularly, and whether the design improves solubility or stability. Their selection connects molecular structure with therapeutic control.
Redox status provides the biological condition that determines whether the glutathione-sensitive linkage is disrupted. Instead of relying only on a drug’s initial chemical activity, the prodrug design couples activation to a reducing intracellular environment. This connection may help regulate when the therapeutic payload becomes available and explains the method’s relevance to controlled treatment strategies.
The design can target three linked goals: improving drug solubility, increasing stability, and promoting selective intracellular release. A developer therefore considers not only the therapeutic payload but also the glutathione-sensitive linker and the carrier or masking group. The resulting structure is intended to keep the drug suitably handled before activation while enabling release after the intracellular trigger is encountered.
Medicine researchers may use this approach when a therapeutic payload would benefit from delivery that is more controlled inside cells. The overview identifies anticancer agents as a major application and also notes other therapeutics. In these settings, glutathione responsiveness links intracellular redox conditions to release, supporting targeted delivery strategies and more controlled treatment.